SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT07222631
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non Hodgkin Lymphoma
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SB-4826 — DRUG
    Small ubiquitin-like modifier E1 inhibitor
  • Rituximab — DRUG
    Cluster of differentiation 20 blocker

Study Details

The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 twice weekly for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.

Key Dates

Start date
Feb 18, 2026
Status verified
Mar 2026
Primary completion
Feb 28, 2031
Completion
Feb 28, 2033

Study Design

Enrollment
48 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Locally advanced or metastatic solid tumors Phase 1 monotherapy
    Phase 1 dose escalation SB-4826 monotherapy
  • Experimental: Non-Hodgkin lymphoma Phase 1 monotherapy
    Phase 1 dose escalation SB-4826 monotherapy
  • Experimental: Non-Hodgkin lymphoma Phase 1 combination therapy
    Phase 1 dose escalation SB-4826 in combination with rituximab
  • Experimental: Non-Hodgkin lymphoma Phase 2 combination therapy
    Phase 2 dose expansion SB-4826 in combination with rituximab

Primary Outcome Measure

Phase 1 (Dose-Escalation): Recommended phase 2 dose of SB-4826 [ Time Frame: 21 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San DiegoLa JollaCalifornia92093
Experimental Therapeutics Research Team
[email protected]
(858) 822-5354

Find similar trials in La Jolla, CA

By research site
University of California, San Diego· La Jolla, CA

Related Studies